The late follow-up endoscopy as bleeding prevention after the gastric endoscopic submucosal dissection in the patient with thienopyridine derivative or low-dose aspirin and warfarin combinatio
- Conditions
- Gastric adenoma or early gastric cancer(cStage IA)
- Registration Number
- JPRN-UMIN000016475
- Lead Sponsor
- Japan Gastroenterological Endoscopy Society Hokuriku Chapter
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Not provided
1. there is a registration history in this study. 2. including for other carcinomas, there is a history of radiation therapy to the upper abdomen. 3. esophageal lesions, there is a plan of endoscopic therapy at the same time against duodenal lesions. 4. within registration before the 28th there is the endoscopic treatment history with respect to the upper gastrointestinal tract lesions. 5. within 28 days after treatment is scheduled to undergo an endoscopic examination or treatment with respect to the upper gastrointestinal tract. 6. continuous systemic administration of antiplatelet or anticoagulant agents other than low-dose aspirin and warfarin or thienopyridine, or steroids. 7. temporary interruption of non-steroidal anti-inflammatory drugs is impossible from ESD treatment 7 days up to 28 days after ESD treatment. 8. childbearing potential during pregnancy or lactating women. 9. have a psychosis or mental symptoms. 10. activity of bacterial and fungal infections. 11. merged the poor control of hypertension. 12. merged the respiratory disease requiring sustained oxygen administration. 13. principal investigator or researcher has determined to be inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference in the incidence of bleeding rates after ESD between late endoscopy group and no late endoscopy group
- Secondary Outcome Measures
Name Time Method